financetom
Business
financetom
/
Business
/
Tata Chemicals to focus on growing new businesses
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Chemicals to focus on growing new businesses
Jul 25, 2018 10:45 PM

The theme of the Tata Chemicals 79th annual general meeting (AGM) held in Mumbai was 'transform, grow.'

This is much in line with the kind of the transformation that Tata Chemicals has been bringing to the business over the last financial year.

Over the last year, the Tata Group has exited businesses like fertilisers and increased focus on growing segments like food and consumer.

In June 2018, Tata Chemicals completed the sale of its Haldia fertiliser unit in West Bengal and the trading business to Netherlands-based Indorama Holdings.

The company has announced a revised reporting structure, which now breaks up the business into segments like basic chemistry products, consumer products and specialty products.

Addressing shareholders at the AGM, the management said that Tata Chemicals is looking at increasing cost efficiencies across businesses.

The big focus will be on scaling up nascent businesses which have good potential.

One such business is the consumer business. The company already has a presence in salt, spices, pulses and it's looking at scaling this up further.

Tata Chemicals is looking at increasing direct distribution to ensure that products are widely available in the market.

In an earlier Interview to CNBC-TV18, R Mukundan, managing director and chief executive officer, Tata Chemicals had said that the consumer business had the potential to scale up to Rs 5,000 crore over the next 3-4 years.

With its balance sheet significantly strengthened owing to divestments undertaken, the company expects to invest funds in capacity expansion across businesses.

At the end of Q4FY18, Tata Chemicals reported a consolidated net debt of about Rs 1,800 crore and hopes to be debt free very quickly.

With business momentum coming back, Tata Chemicals expects FY19 to be better than FY18.

First Published:Jul 26, 2018 7:45 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Australia's Tabcorp appoints former AFL boss Gillon McLachlan as CEO
Australia's Tabcorp appoints former AFL boss Gillon McLachlan as CEO
Jun 16, 2024
(Reuters) - Australian gambling services firm Tabcorp Holdings ( TABCF ) on Monday appointed former Australian Football League (AFL) boss Gillon McLachlan as its chief executive and managing director. The appointment comes months after former chief Adam Rytenskild resigned over allegedly using offensive and inappropriate language at the workplace and as the firm navigates a strategic transformation amid heightened competition...
Currencies consolidate as dollar steadies, euro hangs near one-month low
Currencies consolidate as dollar steadies, euro hangs near one-month low
Jun 16, 2024
TOKYO (Reuters) -The dollar was firm on Monday as the euro hovered near a more than one-month low amid political turmoil in Europe, while investors awaited fresh clues on the strength of the U.S. economy. Investors have been contemplating the risk of a budget crisis at the heart of the euro area, as far right and leftist parties gain momentum...
UBS to book $0.9 billion provision linked to inherited Greensill funds
UBS to book $0.9 billion provision linked to inherited Greensill funds
Jun 16, 2024
ZURICH (Reuters) - UBS expects to record a provision of around $0.9 billion, the Swiss bank said on Monday, in connection to Credit Suisse's funds linked to collapsed supply chain financing firm Greensill Capital. The Credit Suisse Supply Chain Finance Funds have made an offer to redeem fund units, UBS said. Fund investors who choose to accept the offer will...
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
Jun 16, 2024
June 17 (Reuters) - AstraZeneca's ( AZN ) blockbuster cancer drug Imfinzi combined with chemotherapy has been approved in the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient, the drugmaker said. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved